Issued 2026-08-13 at $6.95 · now $6.67 (2026-08-13, −4.0% since)
Based on its own history, a month from the 2026-08-13 close, VSTM has typically landed between $4.66 and $10.05 — a range of −32.9% to +44.6% from the issuance price $6.95.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
3,633 overlapping 1 month windows · 2012-01-27 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($6.95) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where VSTM has typically landed a month from the 2026-08-13 close of $6.95 — the range is history, not a prediction.
- now $6.67 (-4.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $6.83 (-1.7%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $5.67–$7.99
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.66–$10.05
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-05-22 | −75.3% | −75.3% | +2.5% |
| 2024-05-23 | −74.8% | −75.9% | +0.0% |
| 2024-05-21 | −74.3% | −74.3% | +1.0% |
| 3 best | |||
| 2023-04-27 | +166.7% | +0.0% | +166.7% |
| 2023-04-28 | +161.5% | +0.0% | +166.7% |
| 2023-05-01 | +128.4% | −9.1% | +136.4% |
3,633 overlapping windows · 2012-01-27 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-08-31 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (source, as of 2026-08-14)
- June 2027 — Trial primary completion: Phase 2 primary completion: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer (source, as of 2026-08-14)
- June 2027 — Trial primary completion: Phase 2 primary completion: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer (source, as of 2026-08-14)
- June 2027 — Trial primary completion: Phase 2 primary completion: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer (source, as of 2026-08-14)
- 2028-10-15 — Trial primary completion: Phase 3 primary completion: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (source, as of 2026-08-14)
- December 2028 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~15 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.